Ticker News
$AZTR News
Stored TradersLink news articles and press-release context for this ticker. Discord alerts link into these article pages when full article text is available.
Published Articles
Latest saved alerts
Azitra (AZTR) to implement 1-for-10 reverse stock split effective Oct 26, 2026
Azitra (AZTR) will implement a 1-for-10 reverse stock split effective 12:01 AM ET on Oct 26, 2026, with shares trading on a split-adjusted basis on the NYSE American under AZTR when the market opens that day. The split reduces outstanding shares from ~60.6M to ~6.06M, will proportionally adjust equity awards and warrants, and fractional shares will be paid out in cash (without interest) based on the five trading-day pre-split average closing price.
Azitra Q2: ATR‐COSF shows ex‐vivo anti‐wrinkle activity; ATR‐04 enrollment continues, topline Q4'26
Azitra reported Q2 results and disclosed positive preclinical ex vivo human skin data for ATR‐COSF showing repeat‐dose delivery, targeted skin‐layer distribution and anti‐wrinkle activity, supporting advancement toward a planned proof‐of‐concept cosmetic study (human study planned Q3 2026). The company said it is continuing enrollment of the first cohort in the Phase 1/2 ATR‐04 trial for EGFR inhibitor‐associated rash across six sites including MD Anderson with topline cohort data expected in Q4 2026, is advancing recombinant protein initiatives (TEV protease, T7 RNA polymerase), paused further enrollment in the ATR‐12 Phase 1b study to focus capital, and finished the quarter with $6.7M cash and a $3.3M net loss.
Azitra CEO converts 500 Series A prefs into 4.06M common shares
AZTR filed SEC Form 4. Azitra President & CEO Francisco D. Salva reported that 500 shares of Series A Convertible Non‐Redeemable Preferred Stock automatically converted into 4,064,050 shares of common stock effective June 16, 2026, bringing his total beneficial ownership to 4,086,291 shares (which includes 22,241 incentive options exercisable within 60 days). The filing notes the Series A preferred were sold as part of a 'Security' (Series A preferred plus Series B and C warrants) to the reporting person at $1,000 per Security and converted automatically under the Certificate of Designations.
Azitra shifts to cosmeceuticals & recombinant proteins after $10.5M financing
AZTR filed SEC Form 8-K. The company expects to complete an ATR-COSF clinical study in late 2026 with potential partnership/commercialization in 2027 and aims to position the recombinant protein programs for partnering or commercialization within 36 months. Clinical updates: ATR-04 enrollment continues with MD Anderson added as a site and Azitra notes FDA Fast Track designation for EGFR inhibitor–associated rash, while ATR-12 (Netherton syndrome) enrollment is paused to conserve capital.
Azitra pivots to cosmetic recombinant filaggrin and biotech-reagent programs after March financing
Azitra's CEO issued a shareholder letter saying the company reoriented strategy after a March financing ($10.5M raised, plus up to $21M via warrants) to pursue near-term value programs including ATR-COSF, a recombinant filaggrin cosmetic ingredient with ex vivo work ongoing and a clinical study expected to complete late-2026 (partnership/commercialization possible in 2027), and a recombinant-protein reagent push (T7 RNA polymerase, TEV protease) leveraging in-licensed Fred Hutch tech targeting large biotech markets. Existing clinical work continues: ATR-04 (live biotherapeutic for EGFR inhibitor rash) is enrolling with MD Anderson added as a site, while ATR-12 (Netherton syndrome) enrollment is paused after six patients to conserve capital.
Azitra to present pipeline updates and new filaggrin protein/peptide program at BIO 2026
Azitra said Cofounder/COO Travis Whitfill will present at the BIO International Convention on June 23 to highlight pipeline progress and the launch of a filaggrin-based protein and peptide program targeting cosmetic/cosmeceutical markets. The release reiterates clinical programs ATR-12 (Phase 1b for Netherton syndrome) and ATR-04 (EGFR inhibitor–associated rash; FDA Fast Track, open IND) and notes the company will hold one-on-one meetings with investors and potential partners to discuss milestones.
Azitra (AZTR) adjourns annual meeting for lack of quorum; reconvenes June 15
Azitra (AZTR) said its June 4, 2026 annual meeting was adjourned because proxies and virtual attendance represented ~17% of outstanding shares, below the 33 1/3% quorum requirement; the company scheduled a reconvened virtual meeting for June 15, 2026 at 11:00 a.m. ET. Management urged stockholders of record as of April 24, 2026 to submit or change proxies by 10:59 a.m. ET on June 15 (mail, internet or phone options) and noted previously submitted proxies remain valid if unchanged.
Azitra (AZTR) to adjourn June 4 annual meeting and reconvene on June 15 to allow more time for proxy voting
Azitra will open its June 4, 2026 virtual annual meeting, immediately adjourn without conducting business, and reconvene the meeting on June 15, 2026 to give shareholders extra time to receive and submit proxy votes following a minor administrative mailing delay. The meeting will remain virtual, the proposals are unchanged, and votes must be received by 10:59 a.m. ET on June 15 to be counted (or can be cast during the reconvened live webcast).